• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biophys J . A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors

tetano

Editor, Senior Moderator
Biophys J


. 2021 Feb 17;S0006-3495(21)00146-6.
doi: 10.1016/j.bpj.2021.01.037. Online ahead of print.
A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors


A Sofia F Oliveira[SUP] 1 [/SUP], Amaurys Avila Ibarra[SUP] 2 [/SUP], Isabel Bermudez[SUP] 3 [/SUP], Lorenzo Casalino[SUP] 4 [/SUP], Zied Gaieb[SUP] 4 [/SUP], Deborah K Shoemark[SUP] 5 [/SUP], Timothy Gallagher[SUP] 6 [/SUP], Richard B Sessions[SUP] 7 [/SUP], Rommie E Amaro[SUP] 4 [/SUP], Adrian J Mulholland[SUP] 8 [/SUP]



Affiliations

Abstract

Changeux et al. recently suggested that the SARS-CoV-2 spike protein may interact with nicotinic acetylcholine receptors (nAChRs), and that such interactions may be involved in pathology and infectivity. This hypothesis is based on the fact that the SARS-CoV-2 spike protein contains a sequence motif similar to known nAChR antagonists. Here, we use molecular simulations of validated atomically detailed structures of nAChRs, and of the spike, to investigate the possible binding of the Y674-R685 region of the spike to nAChRs. We examine the binding of the Y674-R685 loop to three nAChRs, namely the human α4β2 and α7 subtypes and the muscle-like αβγδ receptor from Tetronarce californica. Our results predict that Y674-R685 has affinity for nAChRs. The region of the spike responsible for binding contains a PRRA motif, a four-residue insertion not found in other SARS-like coronaviruses. The conformational behaviour of the bound Y674-R685 is highly dependent on the receptor subtype: it adopts extended conformations in the α4β2 and α7 complexes, but is more compact when bound to the muscle-like receptor. In the α4β2 and αβγδ complexes, the interaction of Y674-R685 with the receptors forces the loop C region to adopt an open conformation, similar to other known nAChR antagonists. In contrast, in the α7 complex, Y674-R685 penetrates deeply into the binding pocket where it forms interactions with the residues lining the aromatic box, namely with TrpB, TyrC1 and TyrC2. Estimates of binding energy suggest that Y674-R685 forms stable complexes with all three nAChR subtypes. Analyses of simulations of the glycosylated spike show that the Y674-R685 region is accessible for binding. We suggest a potential binding orientation of the spike protein with nAChRs, in which they are in a non-parallel arrangement to one another.
 
Back
Top Bottom